Highest-materiality recent filing
Option Care Health Q1 revenue up 1.3% to $1.35B; Adj. EBITDA down 6.3%; updates FY guidance
GAAP diluted EPS $0.29 (+3.6% YoY); adjusted diluted EPS $0.40 (flat).
Option Care Health ups revolving credit facility by $450M to $850M total
Entered Fifth Amendment to First Lien Credit Agreement on March 30, 2026.
Option Care Health Q4 revenue +8.8%, adjusted EPS $0.46; guides 2026 revenue $5.8-6.0B
Q4 net revenue $1,465.4M (+8.8% YoY); GAAP EPS $0.37 (+5.7%); adjusted EPS $0.46 (+4.5%).
Q4 2025 preliminary net revenue $1.46-1.47B; GAAP diluted EPS $0.37-0.39; adj. diluted EPS $0.46-0.49.
Option Care Health Q3 revenue up 12.2% to $1.44B; adjusted EPS $0.45 (+9.8%)
Net revenue $1,435M (+12.2% YoY); adjusted diluted EPS $0.45 (+9.8%).
Option Care Health refinances term loans at lower rate, adds $49.6M incremental debt
Fourth Amendment to credit agreement: existing term loans refinanced with new Term SOFR +1.75% loans maturing Sept 2025 + 7 years.
Option Care Health names Meenal Sethna CFO effective Oct 1; Shapiro steps down after 10 years
Meenal Sethna appointed EVP/CFO effective Oct 1, 2025, succeeding Mike Shapiro who becomes Strategic Advisor through Q1 2026.
Option Care Health Q2 revenue up 15.4% to $1.42B; adjusted EPS $0.41, up 10.8% YoY
Net revenue $1,416.1M (+15.4% YoY); gross profit $269.0M (19.0% margin vs 20.3%).
Option Care Health Q1 revenue +16.3% to $1.33B; adj. EPS $0.40 (+14.3%)
Net revenue $1,333M, up 16.3% YoY; net income $46.7M, diluted EPS $0.28.
Option Care Health Q4 revenue up 19.7% to $1.346B; issues FY2025 guidance
Q4 2024 revenue $1,346.4M (+19.7% YoY); adjusted diluted EPS $0.44 (+15.8% YoY).
Option Care Health reports preliminary Q4/FY2024 results, FY2025 guidance, and $500M buyback
Q4 2024 net revenue $1.34-1.35B (+19-20% YoY); diluted EPS $0.33-0.36; adjusted diluted EPS $0.42-0.45.
Option Care Health Q3 revenue up 17% but EPS flat; cuts FY2024 guidance on IV bag supply disruption
Net revenue of $1,278.5M (+17.0% YoY); gross margin fell to 20.1% from 23.3%.
Option Care Health Q2 2024: revenue +14.8% to $1.23B; net income down 53.6% to $53M
Net revenue of $1,227.2M, up 14.8% YoY; net income of $53.0M ($0.30 EPS) vs $114.4M ($0.63 EPS) in Q2 2023.
Option Care Health shareholders approve 4M share equity plan increase, reelect directors
Amended 2018 Plan approved: share reserve increased by 4,000,000 shares; plan term extended to May 15, 2034.
Option Care Health Q1 revenue up 12.8% to $1.146B; EPS $0.26; cash flow hit by cyber incident
Net revenue $1,146.1M (+12.8% YoY); net income $44.8M ($0.26 EPS) vs $39.2M ($0.21) YoY.
Option Care Health disruption from Change Healthcare cyber incident; >50% claims unprocessed
More than half of claims for services since Feb 21 remain unprocessed due to Change Healthcare outage.
Option Care Health Q4 revenue up 9.5% to $1.12B; EPS $0.32; FY guides $4.6-4.8B
Q4 net revenue $1,124.4M (+9.5% YoY); net income $57.2M ($0.32 EPS) vs $47.5M ($0.26 EPS).
Option Care Health enters $400M revolver, adopts new severance plan, CCO departs
Entered $400M New Revolver Facility (SOFR+1.75% initial) maturing Dec 2028; terminated existing ABL facility.
Option Care Health Q3 net income up 45% to $56.3M; guides FY23 revenue $4.23B-$4.28B
Net revenue $1,093.0M (+7.1% YoY); gross profit margin expanded to 23.3% from 21.4%.
Net revenue $1,069.1M (+9% YoY); gross profit $250.8M (23.5% of revenue) up 15.6%.
Option Care Health terminates merger with Amedisys, receives $106M termination fee
Option Care Health received $106M cash termination fee from Amedisys upon mutual termination of merger agreement.
HSR waiting period for Option Care Health/Amedisys merger expired June 16
HSR Act waiting period with respect to the Amedisys merger expired on June 16, 2023.
Option Care Health beats Q1 estimates, raises FY guidance, announces Amedisys merger
Net revenue $1,015.8M (+10.9% YoY); net income $39.2M ($0.22 EPS), up 29.5%.
Option Care Health to acquire Amedisys in all-stock deal valued at ~$3.6B
Amedisys stockholders receive 3.0213 OPCH shares per AMED share, ~$97.38/AMED based on May 2 close, a 26% premium.
Option Care Health repurchases $75M shares from HC Group Holdings, underwrites 13M share offering
Repurchased 2,475,166 shares from HC Group Holdings I, LLC for $75M at $30.301 per share.
Option Care Health Q4 revenue up 10.8% to $1.03B; authorizes $250M share buyback
Q4 net revenue $1,027.2M (+10.8% YoY); gross profit $231.1M (22.5% of revenue).
Option Care Health Q3 revenue up 14.5% to $1.02B; EPS $0.21; raises full-year guidance
Net revenue $1,020.9M, up 14.5% YoY; gross margin 21.4% vs 22.8% in Q3 2021.
Option Care Health selling stockholder to offer 11M shares at $33.25; company gets no proceeds
Secondary public offering of 11,000,000 shares of common stock at $33.25 per share.
Option Care Health Q2 revenue up 14% to $980.8M; raises FY2022 guidance
Net revenue $980.8M (+14% YoY); net income $33.9M ($0.19 EPS) vs $31.8M ($0.18 EPS).
Option Care Health Q1 revenue $915.8M (+20.6% YoY); net income $30.3M vs loss
Net income of $30.3M ($0.17 EPS) compared to net loss of $2.9M ($0.02 loss) in Q1 2021.
Option Care Health Q4 revenue up 15.2% to $927M; EPS $0.42; two acquisitions
Q4 revenue $927.2M (+15.2%); net income $75.5M ($0.42 EPS incl. $0.17 one-time tax benefit) vs $17.8M ($0.10) prior year.
Option Care Health Q3 revenue $891.9M (+14.1% YoY); raises FY adj. EBITDA guidance
Net revenue $891.9M, up 14.1% YoY; gross profit $203.0M (22.8% margin).
Option Care Health issues $500M 4.375% senior notes due 2029, refinances $600M term loan to 2028
Issued $500M aggregate principal of 4.375% senior notes due 2029 at 100% issue price.
Option Care Health prices $500M 4.375% senior notes due 2029 and $600M amended term loan B
Priced $500M aggregate principal of 4.375% senior notes due 2029 at 100% of par.
Option Care Health reports preliminary Q3 2021 revenue ~$888-893M, up 14% YoY
Preliminary net revenue $888-893M, ~14% growth over prior year Q3.
Option Care Health selling stockholder completes 9.2M share secondary offering at $26.90
HC Group Holdings I, LLC sold 9,200,000 shares of OPCH common stock at $26.90 per share.
On May 5, 2026, Option Care Health, Inc. (the “Company”) announced that Christopher L. Grashoff will depart from his role as Chief Growth Officer of the Company, effective May 8, 2026.
On September 3, 2024, John J. Arlotta, a member of the Board of Directors (the “Board”) of Option Care Health, Inc. (the “Company”), notified the Company of his resignation from the Board, effective on September 6, 2024.
Nitin Sahney, a member of the Board, notified the Company of his resignation from the Board, effective as of the close of business on January 1, 2024
appointed Barbara Bodem and Norman Wright to the Board effective January 2, 2024.
appointed Barbara Bodem and Norman Wright to the Board effective January 2, 2024.
Richard Denness had ceased to serve as the Company’s Chief Commercial Officer, effective December 7, 2023
On January 16, 2023, the Board of Directors of the Company (the “ Board ”) appointed Luke Whitworth, age 42, to serve as Chief Operating Officer of the Company, effective immediately.
On March 25, 2022, Harriet Booker, Chief Operating Officer of Option Care Health, Inc. (the “Company”), notified the Company that she intends to resign from her COO position with the Company.
On September 17, 2021, Clifford Berman, Senior Vice President, General Counsel and Corporate Secretary of Option Care Health, Inc. (the “Company”), notified the Company that he intends to retire on March 31, 2022.
On August 11, 2021, Robert Kampstra resigned as the Chief Accounting Officer of Option Care Health, Inc. (the “Company”), effective as of August 25, 2021, in order to pursue other career opportunities.
Max materiality 0.90 · Median 0.65 · Most common event earnings